GCTK
GlucoTrack, Inc.
Healthcare — Medical Instruments & Supplies
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
None
$1.41
$-0.23 (-14.02%)
Price History
52-Week Range
Sign in to add GCTK to a watchlist or set price alerts.
Fundamentals
| Market Cap | $2.18M |
| P/E Ratio (TTM) | 0.06 |
| Forward P/E | - |
| EPS (TTM) | $6.27 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -527.21% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 35.5 |
| Beta | 0.69 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $14.14 |
| 52-Week Low | $0.29 |
| 50-Day Avg | $0.59 |
| 200-Day Avg | $3.14 |
| Avg Volume | $4.52M |
| Volume | 252.0K |
Performance Analysis
BULLISHGCTK shows predominantly bullish signals based on its fundamentals and technicals.
+
Trading near its 52-week low ($0.29), which could present a value opportunity.
~
RSI at 35.5 is in neutral territory.
+
P/E of 0.1 suggests the stock may be undervalued.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Jul 02, 2026 13:11 UTC
Back to Screener Export Report